Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.

Anne Béthune-Volters, Marc Labroquère, S. Guepratte, K. Hacène, Rainer Neumann, Walter P. Carney, Marie-France Pichon

PubMed · 2004 · 24 citations · 0 references

Abstract

Our results show that monitoring serum HER-2/neu levels during metastatic breast cancer can provide a real time assessment of a woman's HER-2/neu status and can provide important information for therapeutic decisions.